Lead Sponsor

St. Paul Heart Clinic

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Greater than or equal to 18 years old
•Impaired glucose tolerance: 2-hr oral glucose tolerance test (OGTT) plasma glucose \>140 mg/dL OR impaired fasting glucose: fasting glucose \> or = 100 mg/dL OR elevated glycosylated hemoglobin: Hemoglobin A1c \> or = 5.7%
•Abdominal obesity: waist circumference \>102 cm (men) and \>88 cm (women)
•Stable cardiovascular medication regimen (or other medications known to affect endothelial function) at least 1 month prior to enrollment and throughout the study

•Type 2 diabetes
•Current use of glycemic control medications within one month of randomization
•Fasting glucose \>126 mg/dL
•Current use of weight loss medication
•Previous weight loss surgery
•History of severe gastrointestinal disease
•Standard clinical contraindications to exenatide or metformin therapy
•Unstable angina
•Heart failure
•Stroke or coronary artery bypass graft within 3 months of screening
•Women who are currently pregnant or planning to become pregnant
•Breastfeeding women
•Clinically significant liver disease
•Creatinine \> 1.5 mg/dL
•Hepatic function greater than 3 times upper limit of normal
•Patients who are mentally incompetent and cannot sign a Patient Informed Consent

Related studies

NCT07286747 · Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

NCT07440147 · Obesity & Overweight, Circadian Rhythm Disorders, and more

NCT02969798 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), and more

NCT06964620 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance

NCT05873322 · Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus, and more

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes